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Abstract
Aim Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in the treatment of
type 2 diabetes. Available sub-group analysis of clinical trials does not allow
a clear identification of predictors of therapeutic response to these drugs.
The aim of this study is the assessment of predictors of response to DPP-4
inhibitors.
Materials and methods A meta-analysis was performed, exploring correla-
tion between 24-week effects on HbA1c of maximal doses of DPP-4 inhibitors,
compared either with placebo or with other active drugs, matches to baseline
characteristics of patients enrolled in 63 randomized clinical trials, either
published or unpublished but disclosed on different websites were studied.
Results DPP-4 inhibitors significantly reduce HbA1c at 24 weeks [by
0.6 (0.5–0.7)%] when compared with placebo; no difference in HbA1c
was observed in comparisons with thiazolidinediones and α-glucosidase
inhibitors, whereas sulfonylureas and metformin produced a greater reduc-
tion of HbA1c, at least in the short term. DPP-4 inhibitors produced a smaller
weight gain than thiazolidinediones, and showed a lower hypoglycaemia
risk than sulfonylureas. The placebo-subtracted effect of DPP-4 inhibitors
on HbA1c was greater in older patients and in those with lower fasting
plasma glucose at baseline. Similar results were obtained in comparisons
with thiazolidinediones and metformin.
Conclusions Although drugs for type 2 diabetes are studied in heteroge-
neous samples of patients, their efficacy can be predicted by some clinical
parameters. DPP-4 inhibitors appear to be more effective in older patients
with mild/moderate fasting hyperglycaemia. These data could be useful for
a better definition of the profile of patients who are likely to benefit most
from these drugs. Copyright  2011 John Wiley & Sons, Ltd.
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Introduction
The number of available drugs for the treatment of type 2 diabetes has
substantially increased over the last decade; at present, it includes metformin,
sulfonylureas, glinides, insulin, thiazolidinediones, α-glucosidase inhibitors,
glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 (DPP-
4) inhibitors. Further classes of drugs (e.g. SLGT-2 inhibitors) are bound
to be available in the near future. Treatment guidelines issued by Scientific
Societies and other authorities all agree on the need for an accurate control
of blood glucose for the prevention of long-term complications of diabetes;
however, algorithms and recommendations for pharmacological treatment of
Copyright  2011 John Wiley & Sons, Ltd.
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hyperglycaemia in type 2 diabetic patients differ from
one guideline to another [1–5]. Most experts agree that
metformin should be considered the first-line drug, unless
contraindicated, whereas the choice of the agent to be
combined with metformin in case of monotherapy failure
is controversial. In fact, in randomized clinical trials
(RCTs), different classes of drugs show a similar efficacy
on medium-term HbA1c when combined with metformin
[6].
If two drugs have the same mean effect on HbA1c
in a comparative trial, this does not exclude the
possibility that specific sub-populations of patients are
more responsive to either one or the other agent.
In clinical practice, most physicians use a variety of
hypoglycaemic drugs, empirically selecting for each
patient the pharmacological approach which, in their
opinion, is likely to yield the greatest benefits. In other
words, clinicians identify different patient profiles to
predict responses to different treatments. This process is
based on pathophysiological considerations, mechanistic
reasoning, and personal experience, but it is not supported
by evidence. In fact, a large majority of RCTs includes
a rather wide population of patients; furthermore, pre-
specified or post hoc analyses on sub-groups of patients,
identified by specific clinical characteristics, are seldom
available.
A possible alternative approach to the identification of
predictors of treatment response is represented by meta-
regression. This analysis, which includes results of RCTs,
can be used to explore the correlation between efficacy
and baseline clinical features of patients enrolled, thus
providing information on characteristics associated with
a greater therapeutic response. The aim of this study is the
assessment of predictors of response to DPP-4 inhibitors.
Methods
A meta-analysis was performed including all RCTs with
a duration of at least 21 weeks, either with a cross-
over or with a parallel series design, enrolling patients
with type 2 diabetes, comparing DPP-4 inhibitors with
placebo or active drugs (oral hypoglycaemic agents
and/or insulin) different from other DPP-4 inhibitors.
Trials with a shorter duration were excluded, due to
the fact that they could not yield relevant information
on glycated haemoglobin, which had been chosen
as the principal outcome variable. Trials enrolling
non-diabetic, or type 1 diabetic, subjects were also
excluded. Only trials with maximal doses of DPP-4
inhibitors were included (sitagliptin and vildagliptin
≥100 mg/day, saxagliptin ≥0.5 mg/day, alogliptin ≥25
mg/day, and linagliptin ≥5 mg/day); when multiple
doses were tested, only groups receiving a daily
dose exceeding the thresholds specified above were
considered.
An extensive Medline and Embase search for
‘vildagliptin’, ‘sitagliptin’, ‘saxagliptin’, ‘alogliptin’, and
‘linagliptin’ was performed, collecting all RCTs on humans
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Figure 1. Funnel plot of standard error by standardized
difference in means (HbA1c at 24 weeks)
up to 1st November, 2009. The identification of relevant
abstracts, the selection of studies based on the criteria
described above, and the subsequent data extraction were
performed independently by two of the authors (E. M. and
M. M.), and conflicts resolved by the third investigator (N.
M.). The quality of trials was assessed using some of the
parameters proposed by Jadad et al. [7]. The score was
not used as a criterion for the selection of trials, whereas
some items were used only for descriptive purposes.
Completed but still unpublished trials were identi-
fied through a search of www.clinicaltrials.gov web-
site. The results of those trials were retrieved, if
available, on www.clinicaltrials.gov, www.merck.com/
mrl/clinical trials/results.html, www.novartisclinicaltri
als.com, or www.clinicalstudyresults.org; Food and
Drug Administration (www.fda.gov) and European
Medicines Agency (www.ema.europa.eu) reviews of
approved drugs were also searched for retrieval of
unpublished trials. These sources were also used for
complete information on results of published tri-
als, when not reported in publications. For all pub-
lished trials, results reported in papers were used
as the primary source of information, when avail-
able.
The principal outcome was the effect of DPP-4
inhibitors, compared with other hypoglycaemic agents
or placebo, on HbA1c at 21–30 weeks. For trials with
longer duration, HbA1c at 21–30 weeks was considered,
in order to avoid the possible interference of duration
of treatment. Secondary outcomes included body mass
index (BMI) at the end of the trial. Furthermore, data on
the incidence of any hypoglycaemia (number of patients
with at least one event) and severe adverse events
were extracted. Furthermore, cases of cardiovascular
events (defined as myocardial infarction, angina pectoris,
coronary artery revascularization, chronic heart failure,
stroke, and arteriopathy of lower limbs) reported
as severe adverse events were considered, together
with death by any cause. Microvascular complications
of diabetes were not considered, because of the
relatively short duration of the trials included in the
meta-analysis.
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Figure 2. Trial flow diagram. RCT, randomized clinical trial; T2, type 2
Separate analyses were performed for trials with
different DPP-4 inhibitors, whenever possible.
Heterogeneity was assessed by using I2 statistics. If
a low heterogeneity was detected, we applied both
random-effect and fixed-effect models. We report the
results of the random-effect models because the validity
of tests of heterogeneity can be limited with a small
number of component studies. To estimate possible
publication/disclosure bias caused by the tendency
of published studies to be positive, we used funnel
plots (Figure 1), the Begg adjusted rank correlation
test [8,9], including published and unpublished, but
disclosed, trials. However, because these tests have low
statistical power when the number of trials is small
[10], undetected bias may still be present. Standardized
mean differences were calculated for HbA1c and BMI,
whereas Mantel–Haenszel odds ratio (MH-OR) with 95%
confidence interval was calculated for hypoglycaemia,
and the adverse events defined above, on an intention-
to-treat basis, excluding trials with zero events. A
meta-regression was performed to assess the effect of
putative moderators on the reduction (versus placebo
or comparators) of HbA1c at 21–30 weeks. Moderators
considered included HbA1c, mean age, duration of
diabetes, BMI, and fasting plasma glucose (FPG); the
FPG:HbA1c ratio was also considered among moderators,
as a proxy measure of post-prandial hyperglycaemia. All
analyses were performed using Comprehensive Meta-
analysis Version 2, Biostat (Englewood, NJ, USA) and
SPSS 16.0.
Results
The trial flow is summarized in Figure 2. A total of 33 stud-
ies were retrieved through Medline/Embase; further 30
trials were identified through the www.clinicaltrials.gov
register. For 11 of 30 unpublished trials, some information
could be retrieved from different websites. The European
Medicines Agency and Food and Drug Administration
reviews did not allow the identification of any further
study, although they were useful for the retrieval of some
information (particularly on adverse events), which was
not reported in publications of some trials. The remaining
15 unpublished trials, planning to enrol 10 889 patients
(5863 patient × years), were not disclosed and therefore
excluded from the analysis (Table S1, Supporting Infor-
mation). The meta-analysis included 44 trials; 33 and 15
of those were placebo controlled and active comparator
controlled, respectively, whereas two trials included both
placebo and active comparator arms. The characteristics
of those trials are summarized in Table S2 (see Supporting
Information) and Tables 1 and 2.
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Table 1. Moderators in individual studies included in the meta-analysis
Number of Trial duration Age range Duration of
Study (Ref.) patients (ID/C) (weeks) Age (years) (years) DM (years)
Vildagliptin versus Placebo
Garber [11] 132/144 24 58 18–80 7
Garber [12] 138/138 24 54 18–80 5
Fonseca [13] 144/152 24 59 18–80 15
Rosenstock [14] 148/161 24 51 18–80 2
Pi-Sunyer [15] 174/92 24 51 18–80 2
Bosi [16] 185/182 24 54 18–78 6
Goodman [17] 248/122 24 55 18–78 NR
CLAF237ADE0214 268/127 24 61 18–85 NR
Dejager [18] 293/149 24 53 18–80 2
Bosi [19] 295/294 24 52 18–78 2
Vildagliptin versus Metformin
Schweizer [20] 169/166 24 71 18–75 3
Bosi [19]a 300/294 24 52 18–78 2
CLAF237A23104 456/458 24 57 NR 5
Schweizer [21] 526/254 52 52 18–78 1
Vildagliptin versus Pioglitazone
Rosenstock [14]a 154/161 24 51 18–80 2
Bolli [22] 295/281 24 57 18–77 6
Vildagliptin versus Rosiglitazone
Rosenstock [23] 459/238 24 54 18–80 2
Vildagliptin versus α-Glucosidase inhibitors
CLAF237A1301 188/192 12 60 >20 5
Pan [24] 441/220 24 52 ≥18 1
Vildagliptin versus Glimepiride
Ferrannini [25] 1396/1393 52 57 18–73 6
Sitagliptin versus Placebo
PN-047 102/104 24 72 >65 NR
Rosenstock [26] 163/174 24 56 ≥18 6
Hermansen [27] 222/219 24 56 18–75 8
Charbonnel [28] 226/454 24 54 18–78 6
PN-064 261/259 24 51 ≥18 NR
PN-051 322/319 24 58 ≥21 NR
Aschner [29] 468/247 24 54 18–75 4
Goldstein [30] 551/540 24 53 18–78 4
Raz [31] 96/94 30 55 18–78 8
Chan [32] 65/26 12 67 ≥18 13
PN-052 170/92 54 54 18–78 NR
Sitagliptin versus Metformin
Goldstein [30]a 175/355 24 54 18–78 4
PN-049 528/522 24 56 18–78 NR
Sitagliptin versus Glipizide
Chan [32]a 65/26 52 67 ≥18 13
Nauck [33] 576/559 52 57 18–78 6
Saxagliptin versus Placebo
CV181 038 291/74 24 55 18–77 NR
Rosenstock [34] 306/95 24 53 21–70 2
Jadzinsky [35] 323/328 24 52 18–77 2
CV181 013 375/180 24 54 18–77 5
Chacra [36] 501/267 24 55 18–77 7
DeFronzo [37] 565/179 24 54 18–77 6
Saxagliptin versus Metformin
Jadzinsy [35]a 325/328 24 52 18–77 2
Alogliptin versus Placebo
Rosenstock [38] 260/130 26 55 18–80 12
DeFronzo [39] 264/64 26 53 18–80 NR
Pratley [40] 397/97 26 55 18–80 8
Pratley [41] 401/99 26 57 18–80 8
Nauck [42] 420/104 26 55 18–80 6
NR, not reported.
aStudies with multiple comparators.
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Figure 3. Standardized differences (with 95% confidence inter-
val) of mean HbA1c at 24 weeks in placebo-controlled trials (all
p < 0.001)
The 33 available placebo-controlled trials enrolled 8774
and 5709 patients in active treatment and control groups,
respectively. The Begg adjusted rank correlation test
(Kendall tau −0.14; p = 0.27), calculated on the basis of
21–30-week HbA1c in placebo-controlled trials, suggested
no major publication bias. I2 test for heterogeneity was
62.5%, suggesting the use of a random-effect model. DPP-
4 inhibitors produced a significant reduction of HbA1c
in comparison with placebo at 21–30 weeks (Figure 3),
when used as monotherapy as well as when added to other
glucose-lowering agents [−0.7 (−0.9; −0.6) and −0.7
(−0.8; −0.6), respectively]. In the 14 trials with available
data, DPP-4 inhibitors produced a significant increase
of BMI at 21–30 weeks [0.10 (0.05; 0.15) kg/m2; p <
0.001]. The overall risk of hypoglycaemia (in the 21 trials
with reported events) was greater with DPP-4 inhibitors
than with placebo [MH-OR 1.44 (1.09–1.98); p = 0.024];
however, this difference was entirely due to the trials
in which the drug was used as add-on treatment to
insulin and/on sulfonylureas [MH-OR 2.17 (1.05; 4.49);
p = 0.04]. Conversely, no increased risk of hypoglycaemia
was observed when DPP-4 inhibitors were used as
monotherapy or added to insulin sensitizers [MH-OR
1.05 (0.74; 1.51); p = 0.77]. The risk of serious adverse
events was similar to that observed with placebo (data
not shown). No significant risk of major cardiovascular
events or death was observed in comparison with controls
[MH-OR 1.04 (0.70; 1.55), p = 0.84 and 0.89 (0.36;
1.99), p = 0.64; 17 and 9 trials with at least one major
cardiovascular event and death, respectively].
In the 15 available active comparator studies, which
enrolled 6053 and 5447 patients in DPP-4 inhibitor
and comparator groups, respectively, the effect of DPP-
4 inhibitors on HbA1c at 21–30 weeks was inferior to
that of metformin, while no statistically significant differ-
ences were observed in comparison with sulfonylureas,
thiazolidinediones, and α-glucosidase inhibitors. In active
comparator studies, 21–30-week treatment with DPP-4
inhibitors was associated with a significantly lower BMI
in comparison with thiazolidinediones [−0.10 (−0.21;
−0.01) kg/m2; p = 0.049], whereas no significant dif-
ference was observed with respect to metformin [0.05
(−0.02; 0.13) kg/m2; p = 0.18]. DPP-4 inhibitors were
associated with a lower risk of hypoglycaemia than sul-
fonylureas [MH-OR 0.10 (0.07–0.13), p < 0.01; n = 3
trials], whereas no significant difference was observed in
comparisons with metformin [MH-OR 0.71 (0.24–2.09),
p = 0.53; n = 6 trials] or thiazolidinediones [MH-OR 1.32
(0.30; 5.83), p = 0.71; n = 4 trials]. In direct compar-
isons, the proportion of patients experiencing at least one
serious adverse event was significantly lower with DPP-4
inhibitors than with sulfonylureas [MH-OR 0.78 (0.63;
0.98), p = 0.03; n = 4 trials with events]; no significant
difference was observed in comparisons with metformin,
α-glucosidase inhibitors, and thiazolidinediones [MH-OR
1.01 (0.64; 1.60), 0.58 (0.04; 8.83), and 0.68 (0.38;
1.22), respectively; all p > 0.20]. In the eight active
comparator trials in which information on cardiovascular
events was available, and at least one event was observed,
29 and 45 events were recorded in DPP-4 inhibitors
and comparator groups, respectively [MH-OR 0.66 (0.41;
1.06); p = 0.09]; a significant difference was observed in
the two trials comparing DPP-4 inhibitors with sulfony-
lureas [MH-OR 0.50 (0.25; 0.99); p = 0.05], but not in
the five metformin-controlled studies [MH-OR 0.95 (0.46;
1.96); p = 0.88]. Only 24 deaths (14 and 10 in the DPP-
4 inhibitor and active comparator groups, respectively)
were observed in the 13 trials reporting this informa-
tion (seven of which with events); the limited number of
events prevented any further analysis on this endpoint.
Meta-regression analysis on placebo-controlled trials
showed that DPP-4 inhibitors have a greater efficacy on
HbA1c in older patients, whereas mean values of base-
line HbA1c, FPG, and FPG:HbA1c ratio were all associated
with a smaller effect of DPP-4 treatment on HbA1c, in
comparison with placebo (Figure 4). In comparisons with
metformin, DPP-4 inhibitors showed a greater efficacy in
trials enrolling older patients [slope −0.017 (−0.029;
−0.005), p = 0.006; intercept 1.145 (0.463; 1.827),
p = 0.001] and with lower HbA1c, FPG, and FPG:HbA1c
ratio (data not shown).
Discussion
DPP-4 inhibitors, when compared with placebo, reduce
HbA1c in a relevant manner, either in monotherapy or
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Figure 4. Meta-regression of placebo-subtracted effect on 24-week HbA1c, in relation to average baseline characteristics (age,
HbA1c, FPG, FPG:HbA1c ratio, duration of diabetes, and body mass index) of patients enrolled in each trial. Each dot represents the
difference in HbA1c between active drug and placebo; the size of the dots is proportional to the number of patients enrolled in each
trial
combined with other drugs, without increasing the risk
for hypoglycaemia, unless DPP-4 inhibitors are added
to sulfonylureas and/or insulin. These findings confirm
previous meta-analyses, performed on a smaller number
of clinical trials [43–45]. The modest difference in
endpoint BMI between DPP-4 inhibitors and placebo,
which had been described previously [45], can be easily
explained by the improvement of metabolic control and
the consequent reduction of glycosuria.
DPP-4 inhibitors show a smaller efficacy on HbA1c in
comparison with metformin as previously reported [44].
This difference had already been detected by one 52-week
monotherapy trial, which failed to demonstrate the non-
inferiority of vildagliptin in comparison with metformin
[21]. Conversely, DPP-4 inhibitors are similarly effective
as α-glucosidase inhibitors [22]. Direct comparisons with
thiazolidinediones fail to show any difference in efficacy
on HbA1c; however, most of those studies have a very
short follow-up, and they may underestimate the effect
of PPAR-γ agonists, which have been shown to perform
much better than other classes of drugs in the longer term
[46]. Interestingly, in comparison with sulfonylureas,
DPP-4 inhibitors produce a similar reduction of HbA1c.
The limited number of available data and the small
number of trials with longer duration [25,32] suggest
caution in the interpretation of results; however, the effect
of DPP-4 inhibitors on HbA1c although slower, does not
appear to be inferior to that of sulfonylureas in the longer
term. The possibility that a divergent effect of DPP-4
inhibitors and sulfonylureas on β-cell mass and function,
suggested by some experimental studies [47], produces a
longer-term difference in hypoglycaemic efficacy needs to
be assessed through clinical trials of appropriate duration,
which are currently unavailable.
DPP-4 inhibitors confirm their good tolerability, with
an incidence of severe adverse events similar to placebo,
a lower hypoglycaemic risk than sulfonylureas, and a
lower weight gain than thiazolidinediones. The number
and duration of available trials are still insufficient to
draw definitive conclusions on the cardiovascular effects
of DPP-4 inhibitors; however, these drugs do not seem
to induce any increase in cardiovascular morbidity, or in
overall mortality, in comparison with placebo, confirming
previous observations [44]. Available trials confirm, to
date, the satisfactory cardiovascular safety profile of
DPP-4 inhibitors, whereas further data are needed to
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verify their potential beneficial effects in this respect.
Considering the small number of available trials reporting
complete information on this point, the observed risk
reduction for major cardiovascular events in direct
comparisons with sulfonylureas, although statistically
significant, could be a casual finding.
Clinical trials provide an estimate of the average
effect of a drug on a pre-defined endpoint. However,
in clinical practice, the individual response to each agent
varies from one patient to another. The identification of
clinical predictors of therapeutic responses to individual
agents, or to a class of drugs, could be very useful
for clinicians in their everyday practise. Ideally, this
information should be obtained through pre-defined sub-
group analyses of RCTs; unfortunately, this information
was seldom available. Meta-regression analysis can be
used as an alternative source of information, although
its results should be considered with caution because
of the risk of ecological fallacy [48]. Although meta-
regression can provide useful information, it can at best
be hypothesis generating. For example, a correlation
between the mean age of the respective study populations
and the mean glycaemic effect would not necessarily be
similar to the correlation among all pooled individual
data between age and glycaemic response. In addition,
summarizing studies does not account for potential
differences in study background population which may
affect the response to therapy as well. However, based
on results of available placebo-controlled trials, DPP-4
inhibitors seem to be more effective in older patients
and in those with lower HbA1c and FPG; interestingly,
a lower FPG:HbA1c ratio, which can be considered a
proxy of post-prandial hyperglycaemia, is associated with
a greater placebo-subtracted effect of DPP-4 inhibitors.
These results are confirmed by those obtained in trials
with active comparators. It should be recognized that
the FPG:HbA1c ratio is only a very indirect index
of post-prandial glucose; the direct measurment of
glycaemia after meals would be preferrable. However, the
methods used for measurement of post-prandial glucose
vary widely across trials, preventing any reliable meta-
analysis/meta-regression. The fact that DPP-4 inhibitors
are more effective in patients with prevailing post-
prandial hyperglycaemia is not surprising, considering
that these drugs increase the levels of endogenous
glucagon-like peptide-1 and gastro-intestinal polypeptide,
which are mainly produced after meals. Interestingly,
these drugs seem to have a greater efficacy in older
patients, who show, on average, a greater degree of
impairment of meal-induced insulin secretion and post-
prandial hyperglycaemia than subjects with an earlier
onset of type 2 diabetes. Although data on this point are
conflicting, it has been suggested that ageing could be
associated with disturbances of the incretin axis [49]. The
greater efficacy of DPP-4 inhibitors in older patients was
suggested by a previous meta-analysis of patient-level
data from alogliptin trials, but differences among age
groups did not quite reach statistical significance [50].
In conclusion, these data could be useful for a better
definition of the profile of patients who are likely to
benefit most from DPP-4 inhibitors.
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